News | December 09, 2023
Zepbound is now available in US for adults living with obesity
Express Scripts to add Zepbound to National Preferred Formulary
Express Scripts to add Zepbound to National Preferred Formulary
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The standout story remains Wegovy, particularly its new oral formulation
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
Subscribe To Our Newsletter & Stay Updated
